10X Genomics (TXG) PT Lowered to $12 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts TXG Hot Sheet
Price: $67.52 --0%
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
UBS analyst John Sourbeer lowered the price target on 10X Genomics (NASDAQ: TXG) to $12.00 (from $14.00) while maintaining a Neutral rating.
You May Also Be Interested In
- 10x Genomics launches AI-powered single cell analysis tool
- McKesson (MCK) PT Raised to $965 at RBC Capital
- Arm Holdings (ARM) PT Lowered to $270 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
